These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study. Hershberger E; Sloan S; Narayan K; Hay CA; Smith P; Engler F; Jeeninga R; Smits S; Trevejo J; Shriver Z; Oldach D EBioMedicine; 2019 Feb; 40():574-582. PubMed ID: 30638863 [TBL] [Abstract][Full Text] [Related]
7. A Dose-finding Study of a Wild-type Influenza A(H3N2) Virus in a Healthy Volunteer Human Challenge Model. Han A; Czajkowski LM; Donaldson A; Baus HA; Reed SM; Athota RS; Bristol T; Rosas LA; Cervantes-Medina A; Taubenberger JK; Memoli MJ Clin Infect Dis; 2019 Nov; 69(12):2082-2090. PubMed ID: 30770534 [TBL] [Abstract][Full Text] [Related]
8. A Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans. Pleguezuelos O; Robinson S; Fernández A; Stoloff GA; Mann A; Gilbert A; Balaratnam G; Wilkinson T; Lambkin-Williams R; Oxford J; Caparrós-Wanderley W Clin Vaccine Immunol; 2015 Jul; 22(7):828-35. PubMed ID: 25994549 [TBL] [Abstract][Full Text] [Related]
9. HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy. Gilbert PB; Fong Y; Juraska M; Carpp LN; Monto AS; Martin ET; Petrie JG BMC Infect Dis; 2019 May; 19(1):453. PubMed ID: 31117986 [TBL] [Abstract][Full Text] [Related]
10. Differential Effects of Influenza Virus NA, HA Head, and HA Stalk Antibodies on Peripheral Blood Leukocyte Gene Expression during Human Infection. Walters KA; Zhu R; Welge M; Scherler K; Park JK; Rahil Z; Wang H; Auvil L; Bushell C; Lee MY; Baxter D; Bristol T; Rosas LA; Cervantes-Medina A; Czajkowski L; Han A; Memoli MJ; Taubenberger JK; Kash JC mBio; 2019 May; 10(3):. PubMed ID: 31088926 [TBL] [Abstract][Full Text] [Related]
11. Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study. Memoli MJ; Czajkowski L; Reed S; Athota R; Bristol T; Proudfoot K; Fargis S; Stein M; Dunfee RL; Shaw PA; Davey RT; Taubenberger JK Clin Infect Dis; 2015 Mar; 60(5):693-702. PubMed ID: 25416753 [TBL] [Abstract][Full Text] [Related]
12. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737 [TBL] [Abstract][Full Text] [Related]
13. Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection. Monto AS; Petrie JG; Cross RT; Johnson E; Liu M; Zhong W; Levine M; Katz JM; Ohmit SE J Infect Dis; 2015 Oct; 212(8):1191-9. PubMed ID: 25858957 [TBL] [Abstract][Full Text] [Related]
14. Characterisation of a wild-type influenza (A/H1N1) virus strain as an experimental challenge agent in humans. Watson JM; Francis JN; Mesens S; Faiman GA; Makin J; Patriarca P; Treanor JJ; Georges B; Bunce CJ Virol J; 2015 Feb; 12():13. PubMed ID: 25645025 [TBL] [Abstract][Full Text] [Related]
15. Systematic surveillance of patient-reported symptoms of viral respiratory tract infectious Syndromes in diverse populations. Gander JC; Chrenka E; Cromwell L; Truitt AR; Sesay M; Segall M; Amouzou SA; Hudgins AF; Kodthala P; Roblin D; Deneal AN; Whiting T; Powers JH; Martinson BC BMC Health Serv Res; 2022 Dec; 22(1):1591. PubMed ID: 36581932 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590 [TBL] [Abstract][Full Text] [Related]
17. Development of the Flu-PRO: a patient-reported outcome (PRO) instrument to evaluate symptoms of influenza. Powers JH; Guerrero ML; Leidy NK; Fairchok MP; Rosenberg A; Hernández A; Stringer S; Schofield C; Rodríguez-Zulueta P; Kim K; Danaher PJ; Ortega-Gallegos H; Bacci ED; Stepp N; Galindo-Fraga A; St Clair K; Rajnik M; McDonough EA; Ridoré M; Arnold JC; Millar EV; Ruiz-Palacios GM BMC Infect Dis; 2016 Jan; 16():1. PubMed ID: 26729246 [TBL] [Abstract][Full Text] [Related]
18. Sex Differences in Influenza: The Challenge Study Experience. Giurgea LT; Cervantes-Medina A; Walters KA; Scherler K; Han A; Czajkowski LM; Baus HA; Hunsberger S; Klein SL; Kash JC; Taubenberger JK; Memoli MJ J Infect Dis; 2022 Feb; 225(4):715-722. PubMed ID: 34423369 [TBL] [Abstract][Full Text] [Related]
19. The Dynamic Relationship Between Clinical Symptomatology and Viral Shedding in Naturally Acquired Seasonal and Pandemic Influenza Virus Infections. Ip DKM; Lau LLH; Chan KH; Fang VJ; Leung GM; Peiris MJS; Cowling BJ Clin Infect Dis; 2016 Feb; 62(4):431-437. PubMed ID: 26518469 [TBL] [Abstract][Full Text] [Related]
20. Factor Analysis in Distinguishing Coronavirus Disease 2019 From Other Influenza-like Illness Using a Validated Patient-Reported Outcome Instrument FLU-PRO Plus: A Prospective Real-world Cohort Study. Chrenka EA; Roblin DW; Gander JC; Powers JH; Cromwell LX; Kodthala PX; Whiting TS; Sesay MM; Segall MF; Deneal AN; Truitt AR; Sour EU; Martinson BC Med Care; 2023 May; 61(5):288-294. PubMed ID: 36917774 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]